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Abstract 
Introduction: Conventional markers of Juvenile-onset Systemic Lupus 
Erythematosus (JSLE) disease activity fail to adequately identify Lupus Nephritis 
(LN). While individual novel urine biomarkers are good at detecting LN flares, 
biomarker panels may improve diagnostic accuracy. The aim of this study was to 
assess the performance of a biomarker panel to identify active LN in two international 
JSLE Cohorts. Methods: Novel urinary biomarkers; vascular cell adhesion molecule-1 
(VCAM-1), monocyte chemoattractant protein 1 (MCP-1), lipocalin like 
prostaglandin D synthase (LPGDS), transferrin, ceruloplasmin, alpha-1-acid 
glycoprotein (AGP) and neutrophil gelatinase associated lipocalin (NGAL) were 
quantified in in a cross-sectional study including participants of the UK JSLE Cohort 
Study (Cohort 1) and validated within the Einstein Lupus Cohort (Cohort 2). Binary 
logistic regression modeling and receiver operating curve analysis were used to 
identify and assess combinations of biomarkers for diagnostic accuracy. Results: 91 
JSLE patients were recruited across both cohorts, 31 (34%) had active LN and 60 
(66%) had no LN. Urinary AGP, ceruloplasmin, VCAM-1, MCP-1 and LPGDS levels 
were significantly higher in active LN compared to non-LN patients (all corrected p-
value (pc)<0.05) across both cohorts. Urinary transferrin also differed between patient 
groups in Cohort 2 (pc=0.001). Within Cohort 1, the optimal biomarker panel 
included AGP, ceruloplasmin, LPGDS and transferrin (AUC 0.920 for active LN 
identification). These results were validated in Cohort 2, with the same markers 
resulting in the optimal urine biomarker panel (AUC 0.991). Conclusion: In two 
international JSLE Cohorts, urinary AGP, ceruloplasmin, LPGDS and TF demonstrate 
an ‘excellent’ ability for accurately identifying active LN in children. 
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Introduction 
Juvenile-onset systemic lupus erythematosus (JSLE) is a life-threatening multi-system 
autoimmune disease that displays a more aggressive course than adult onset SLE [1-
3]. More renal manifestations occur in childhood, with up to 80% of JSLE patients 
developing lupus nephritis (LN) within the first 5 years from diagnosis [1,4-9]. LN is 
characterised by a relapsing and remitting course, requiring close surveillance and 
prompt treatment to prevent renal damage. Worldwide, the 5-year renal survival rate 
in children with LN has been shown to vary between 44-94% [10-13]. 
 
Renal histology is the gold standard for diagnosing and predicating renal prognosis in 
LN, but only provides a snapshot of a discrete area of the kidney, and is rarely 
repeated for monitoring purposes due to its invasive nature [14,15]. Composite 
disease activity scores such as the British Isles Lupus Assessment Group (BILAG) 
score or the Systemic Lupus Erythematosus Disease Activity Index (SELENA 
SLEDAI), and a number of traditional clinical biomarkers can be used to assess JSLE 
disease activity; however their role in monitoring LN within the clinic is limited [16-
19]. 
 
Over recent years, numerous individual novel urinary biomarkers have been 
investigated for monitoring LN disease activity, outperforming both traditional and 
novel serum biomarkers, including monocyte chemoattractant protein-1 (MCP-1), 
neutrophil gelatinase associated lipocalin 1 (NGAL), vascular cell adhesion molecule-
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1 (VCAM-1) and tumour necrosis like weak inducer of apoptosis (TWEAK) [20-26]. 
Using a proteomic approach, urinary transferrin, ceruloplasmin, lipocalin-type 
prostaglandin D synthase (LPGDS), AGP, albumin and albumin fragments have been 
shown to differentiate between children with active LN and no LN [27]. When 
assessed longitudinally, LPGDS, AGP and transferrin were all elevated up to 3 
months before LN flare [27]. 
 
No individual urine biomarker has achieved an ‘excellent’ predictive value 
(AUC>0.9) to date. Combining urinary biomarkers in a ‘biomarker panel’ has been 
shown to improve the ability to predict renal function loss in a combined pediatric / 
adult SLE cohort LN [28] and relate to LN histological features [29] and activity [30]. 
This study therefore aimed to build on previous work [22,25-27,31-33] by exploring 
the most promising candidate urinary biomarkers to date used in combination, namely 
VCAM-1, MCP-1, NGAL, ceruloplasmin, transferrin, LPGDS, and AGP in a 
pediatric cohort from the UK (UK JSLE Cohort Study), to assess which novel 
biomarker combinations can improve the identification of active LN. Since the JSLE 
phenotype and disease severity varies by ethnicity and race [2,4,34], we sought to 
confirm our results in a validation cohort from the US (Einstein Lupus Cohort, ELC) 
[35] to identify a urinary biomarker panel which is internationally applicable. Such a 
transatlantic comparison of a biomarker panel provides considerable strength to this 
study and the validation of this panel.  
 
Methods 
 
Patients 
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This study was based on two cross-sectional JSLE Cohorts: the exploratory UK JSLE 
Cohort [1], which included all recruited patients from Alder Hey Children’s NHS 
Foundation Trust, Liverpool, and Great Ormond Street NHS Hospital for Children, 
London, UK. The validation cohort included ELC patients who were followed 
regularly at lupus clinics at the Children’s Hospital at Montefiore, Bronx, NY, USA 
[35]. In both cohorts, urine samples were collected during routine clinical care 
together with detailed demographic data, self reported ethnicity / race data, clinical 
laboratory results and medication information. Disease activity data was determined 
using the BILAG2004 disease activity score [36,37]. Eligible patients were diagnosed 
with JSLE prior to 16 years of age and met ≥4 of the revised American College of 
Rheumatology (ACR) SLE classification criteria [38]. Patients were excluded if they 
had a urinary tract infection or if no urine samples had been collected.  
 
Compliance with Ethical Standards 
The research was carried out in accordance with the declaration of Helsinki. Patient 
assent / consent and parental consent was obtained to participate in the studies, and 
full ethical approvals were in place from the National Research Ethics Service North 
West, Liverpool East, UK (reference 06/Q1502/77) and the Institutional Review 
Board at Einstein-Montefiore (IRB 2000-154). The authors do not have any financial 
interests that could create a potential conflict of interest or the appearance of a conflict 
of interest with regard to the work. 
 
Renal disease activity classification 
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Patients were categorized according to the renal domain of BILAG2004 disease 
activity score, defined as follows; BILAG2004 grade A / B: severe, moderate disease 
respectively, grade D: inactive disease but previous system involvement, grade E: 
system has never been involved [37]. The composite renal BILAG score consisted of 
six items, including proteinuria (defined in terms of urine dipstick or urine protein / 
albumin creatinine ratio or 24 hour protein levels), deteriorating renal function (based 
on plasma creatinine and GFR), presence of active urinary sediment, hypertension, 
nephrotic syndrome and histological evidence of active nephritis in the previous three 
months, with different test score cut-offs relating to the different disease activity 
categories. In both cohorts, all active LN patients had biopsy-proven LN during their 
disease course. Renal disease activity was therefore defined as having a renal 
BILAG2004 score of A or B with previous histological confirmation of LN. Non-LN 
was defined by a renal BILAG2004 score of D or E. This study sought to identify 
biomarkers that differentiate between the binary outcome of active vs. no LN, 
therefore renal BILAG2004 C patients (where a patient had mild or improving renal 
disease) were excluded. 
 
Urine sample selection 
In Cohort 1, when more than one patient urine sample had been collected, urine 
biomarkers were quantified in a single sample for inclusion within this study (cross-
sectional approach). An active LN sample was chosen for inclusion where available, 
to allow as many active LN patients as possible to contribute to the study. If a patient 
contributed an in-active LN sample, then the first sample collected with adequate 
aliquots for quantification of the whole biomarker panel was included. In Cohort 2, 
23/30 study patients had an active LN sample available and 14/30 had in-active LN 
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(non-LN) sample available.  Urine biomarker levels were quantified in all samples, 
however, 16 of these active-LN and all 14 non-LN samples contributed to the cross-
sectional analysis, to provide similar patient numbers per group. The other 7 active-
LN samples were subsequently included in analyses comparing urine biomarker 
concentrations in biopsy vs renal BILAG defined active LN.  
 
Extra-renal disease activity classification 
To allow assessment of biomarker levels according to whether extra-renal JSLE 
disease activity was present or not, patients were subdivided further as having ‘any 
active extra-renal involvement’ if they had a BILAG2004 of A or B in any of the 
remaining domains (constitutional, mucocutaneous, neuropsychiatric, 
musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic or haematological) or 
‘no extra-renal involvement’ if they had a BILAG2004 score of D or E in all extra-
renal domains. Biomarker levels were therefore compared in active / non-LN patients 
with and without extra-renal involvement.  
 
Laboratory techniques 
Urine dipstick and / or microscopy and culture excluded infection. Samples were 
centrifuged at 2000 rpm for 10 minutes. Urine supernatant was aliquoted and stored at 
-80oC. Pre-coated enzyme-linked immunosorbent assay (ELISA) kits were used for 
quantification of urinary Ceruloplasmin (St Charles, Assay Pro, USA), transferrin 
(GenWay, San Diego, USA), LPGDS (BioVendor, Brno, Czech Republic), AGP and 
MCP-1 (R&D Systems Ltd, Minneapolis, USA). An R&D systems duo-kit (R&D 
Systems Ltd, Minneapolis, USA) was used to quantify urinary VCAM-1 following 
internal validation (95% spike recovery, 104% linearity of dilution, co-efficients of 
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inter / intra-assay variability 5.1 and 7.5% respectively). The Ceruloplasmin, LPGDS, 
MCP-1 and AGP assays are commercially validated for use in urine and used as per 
manufacturers instructions. Urinary NGAL and creatinine concentrations were 
measured using Abbott Architect assays (Abbott Laboratories, Texas, USA). All 
biomarker results were standardised for urinary creatinine (Cr) concentration and 
presented in units per milligram creatinine (mgCr). 
 
Statistical analysis 
Summary statistics for demographics (age at diagnosis, current age, gender, ethnicity), 
baseline clinical data (medication use and laboratory parameters) and biomarker data 
(Ceruloplasmin, Transferrin, LPGDS, MCP-1, VCAM-1, AGP and NGAL) were 
provided in terms of median values and interquartile ranges (IQR). Univariate logistic 
regression (quantitative data) and Pearson’s chi-square test (binary data) were used to 
assess for differences in demographic and clinical factors between different patient 
groups. Due to the number of factors explored, a Bonferroni adjustment was applied 
to account for multiple testing (16 comparisons per cohort). 
 
Mann Whitney U tests with Bonferroni adjustments were used to compare biomarker 
concentrations between active and non-LN patients (7 comparisons). Correlation 
between the individual urine biomarkers was assessed using Spearman’s rank 
correlation tests. Grading of correlataion co-efficients (r) can vary but for the 
purposes of this study was defined as 0.2-0.3 = weak / little correlation, 0.3-0.7 = 
moderate, 0.7-1.0 = strong correlation  [39]. A binary logistic regression model was 
fitted to assess for association between a combination of biomarkers and LN status 
(outcome: LN active=1; non-LN JSLE=0). All novel biomarkers (log-transformed) 
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were included in an initial model and the ‘stepAIC’ function in R [40] applied to 
select a final model. This function compares models based on all possible 
combinations of biomarkers and chooses the model with the minimum AIC (Akaike 
Information Criterion) value. The AIC is a measure of the relative quality of a model 
relative to each of the other models, with a lower value meaning better quality.The 
AUC for the final model was calculated.  Each of the remaining novel biomarkers 
were then added back into the final model in turn, in order of statistical significance 
according to the original model including all novel biomarkers, and the AUC for each 
updated model calculated. This allowed exploration of the effect of each biomarker on 
the model’s AUC, as well as an assessment of which combination of biomarkers led 
to the optimal AUC. This final process was repeated in the ELC validation cohort in 
order to determine whether the findings could be replicated. The data was then pooled 
to identify the optimal combined model. AUC values of 1.0–0.9, 0.9–0.8, 0.8–0.7, 
0.7–0.6, 0.6–0.5 were considered “excellent, good, fair, poor and fail” respectively 
[41]. 
 
To assess the renal specificity of the urine biomarkers and whether biomarker levels 
vary according to whether extra-renal JSLE disease activity is present, biomarker 
levels in patients with ‘any active extra-renal involvement’ were compared to those 
with ‘no extra-renal involvement’ (Mann Whitney U tests with a Bonferroni 
adjustment for the 7 biomarkers examined). Similarly, when comparing urinary 
biomarker levels in patients where a diagnosis of LN was made on the basis of recent 
renal biopsy results versus BILAG defined nephritis alone, Bonferroni adjusted Mann 
Whitney U tests were also used. The ability of traditional biomarkers to identify 
active LN was investigated using binary logistic regression models for each / a 
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combination of biomarkers (log-transformed) and LN status, and the AUC calculated. 
 
Data analysis was undertaken using Statistics Package for Social Sciences (SPSS Ltd, 
USA) version 21.0 and R version 3.1.1 [40]. Graphical illustrations were generated 
using GraphPad Prism version 6.0. Where Bonferroni adjustment was made to 
account for multiple testing, the Bonferroni corrected p-value, pc is reported. 
 
Results 
 
Cohort 1 - Exploratory Cohort (UK JSLE Cohort Study) 
 
Clinical and demographic data 
The UK JSLE study cohort consisted of 61 JSLE patients, 15 (25%) were classed as 
JSLE active LN (2/15 renal BILAG score=A, 13/15=B) and 46 (75%) as JSLE non-
LN patients (27/46 renal BILAG score=D, 19/46=E). Active and non-LN JSLE 
patients had a median age of 15.8 [14.8-17.1] and 15.4 [13.8-17.5] years respectively, 
with disease duration of 2.8 [0.7-3.9] and 2.4 [0.8-4.8] years at the time of biomarker 
analysis. Females comprised 86.7% of the active LN patients and 62.5% of the non-
LN patients. There was no difference in ethnicity between patient groups.  All JSLE 
patients had a median of 5 ACR classification criteria at diagnosis [IQR 4-7]. All 
active LN patients had biopsy proven LN during their disease course, with the 
majority having International Society of Nephrology/Renal Pathology Society 2003 
(ISN/RPS) class III (59%) or IV (27%) LN. Class II (7%) and mixed class II/V (7%) 
LN was seen in the remaining patients (see Table 1). 
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More active LN patients had received Rituximab (pc<0.05) but use of other 
medications did not differ significantly between the patient groups. Of the laboratory 
parameters investigated, urine albumin-to-creatinine ratio (UACR) and erythrocyte 
sedimentation rate (ESR) were significantly higher in the active LN patients (all 
pc<0.05) (see Table 1). 
 
Novel urinary biomarkers 
Figure 1 depicts the distribution of novel urinary biomarker concentrations 
standardized to urinary creatinine in patients with active LN and no LN. Patients with 
active LN had significantly higher urinary concentrations of AGP, ceruloplasmin, 
VCAM-1, MCP-1, and LPGDS than non-LN patients (all pc<0.05, see Figure 1 and 
Online Resource 1). Urinary Transferrin and NGAL concentrations did not differ 
significantly between the patient groups (pc = 0.06 and 1.0 respectively, see Figure 1 
and Online Resource 1). LPGDS and AGP were strongly correlated (r = 0.71). All 
other biomarker combinations were moderately correlated (r = 0.3-0.7) except 
LPGDS + TF and MCP-1 + TF which were weakly correlated ( r < 0.3, see on-line 
resource 2 for further details). 
 
Urine biomarker levels did not differ between non-LN patients who had previous LN 
(renal-BILAG score D) and those with no previous renal involvement (renal-BILAG 
score E, all pc>0.05). Similarly, there was no difference between patients with severe 
or moderate active LN (renal-BILAG score A / B respectively, all pc>0.05, see on-
line resource 3). There was also no significant difference in urinary biomarker levels 
depending on the presence or absence of extra-renal involvement (see Figure 2). 
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On fitting a binary logistic regression model including all novel biomarkers, and 
applying the ‘stepAIC’ function in R [40], the final model included both AGP and 
Ceruoplasmin (see Table 2). AUC for this final model was 0.88. On addition of 
LPGDS, the AUC increased to 0.90, increasing further to 0.92 on addition of 
transferrin. Addition of VCAM-1 and MCP-1 into the model however, did not 
increase the AUC (see Table 3). 
 
Cohort 2 - Validation Cohort (Einstein Lupus Cohort) 
 
Clinical and demographic data 
The validation cohort consisted of 30 JSLE patients, 16 (53%) were classed as active 
LN (11/16 renal BILAG score=A, 5/16=B) and 14 (47%) as non-LN JSLE patients 
(6/16 renal BILAG score=D, 8/16=E). Active and non-LN JSLE patients had a 
median age of 15 and 18 years respectively, with a disease duration of 3.1 and 1.7 
years at the time of biomarker analysis. One hundred percent of the active LN and 
71% of the non-LN patients were female. Both JSLE patient groups had a median of 5 
ACR classification criteria at diagnosis. ELC patients were largely African / African 
American (53%) and Hispanic (43%), wheras UK JSLE Cohort patients were 
predominatly Caucasian (41%) and Indian (23%). All active LN patients had biopsy 
proven LN during their disease course, with the ISN/RPS 2003 classess as follows; 
class III = 19%, class IV = 19%, class V = 31%, mixed class III/V = 31%. Both 
groups of patients had a median of 5 ACR classification criteria at diagnosis. Active 
LN and non-LN patients differed significantly in terms of their UACR and use of 
angiotensin converting enzyme inhibitors (ACEi) / angiotensin 2 blockers (AT2) 
(both p<0.05, see Table 1). 
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Novel urine biomarkers 
Figure 1 shows the distribution of novel urinary biomarker concentrations in Cohort 
2, relative to Cohort 1 patients. Patients with active LN had significantly higher 
urinary concentrations of AGP, ceruloplasmin, LPGDS, TF, MCP-1 and VCAM-1 
than non-LN patients (all pc<0.05). NGAL levels did not differ between patient 
groups in either cohort (pc=1.0). CP and MCP-1, AGP, TF were all strongly 
correlated. LPGDS was also strongly correlated with AGP and VCAM-1. AGP was 
strongly correlated with VCAM-1 and TF (all r > 0.7). All other biomarker 
combinations were moderately correlated (r = 0.3-0.7, see on-line resource 2 for 
further details). 
 
A binary logistic regression model was fitted with Cohort 2 data, adding them in a 
stepwise manner one at a time in the same order as was done for Cohort 1. The model 
including AGP, ceruoplasmin, LPGDS and transferrin again produced the optimal 
AUC (0.991). As a combination of biomarkers led to excellent identification of active 
LN in both cohorts, AUCs were also calculated for both cohort datasets combined 
(see Table 3). A combined Cohort 1 and Cohort 2 model, including AGP, 
Ceruoplasmin, LPGDS and Transferrin again gave excellent AUC (0.949), however 
adding VCAM-1 slightly improved the AUC further (0.952). The receiver-operating 
curve (ROC) generated by this optimal Cohort 1 and 2 model is shown in Figure 3. 
 
Urine biomarker concentrations in biopsy vs renal BILAG defined active LN 
Urine biomarker levels from twelve samples from Cohort 2 patient which were taken 
at the time of or within 6 weeks of renal biopsy, were compared with eleven patient 
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samples with a current composite renal BILAG score-based diagnosis of active LN 
(but a previous history of having had biopsy defined active LN). Urinary AGP, CP, 
LPGDS, TF, MCP-1 and VCAM-1 levels did not differ significantly between the two 
groups of active LN patients (all pc = 1.0; see Figure 4). Cohort 1 urine samples were 
not available close to the time of renal biopsy, therefore comparable groups were not 
available for inclusion in these analyses. The study was underpowered to assess for 
differences in any of the urinary biomarkers according to ISN/RPS 2003 sub-class. 
 
Ability of traditional biomarkers to identify active LN 
Traditional biomarkers which do not contribute to the composite renal BILAG score 
were assessed for their ability to identify active LN. ESR was the best traditonal 
biomarker with a fair AUC of 0.796 (ESR only measured routinely within cohort 1). 
C3 and dsDNA showed a poor ability to identify active LN in both cohorts (AUC’s 
from 0.617-0.645). C4 performed worst with an AUC or 0.593 and 0.482 in cohort 1 
and 2 respectively. Inclusion of all traditional biomarkers together in a regression 
model did not improve the AUC. Addition of ESR - the best traditional biomarker - to 
the optimal UK novel biomarker combination, including AGP, LPGDS, Transferrin 
and Ceruloplasmin, did not improve the AUC further (AUC 0.910, see Table 4). 
 
Discussion 
To optimise effective management of LN, readily available and easily measured 
biomarkers are urgently needed within clinical practice. Early diagnosis and prompt 
treatment of LN can improve long-term renal survival [18]. The invasive nature of 
renal biopsy limits its clinical utility, especially in childhood. By simultaneously 
measuring urinary AGP, ceruloplasmin, VCAM-1, transferrin, LPGDS, MCP-1 and 
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NGAL at a single patient visit in two ethnicially diverse cohorts of JSLE patients, the 
aim of this study was to derive and internationally validate a biomarker panel which 
could improve identification of active LN, over and above individual biomarkers. 
Across both cohorts we have demonstrated an optimal urine biomarker combination 
including AGP, Ceruoplasmin, LPGDS and Transferrin with excellent AUC values 
for active LN identification (0.920 and 0.991 for Cohorts 1 and 2 respectively). 
Furthermore, the presence of extra-renal disease activity does not appear to influence 
the accuracy of these urine biomarkers. This is therefore the first LN urine biomarker 
panel study to include a exploratory and validation cohort, providing a firm 
foundation for future development of a clinical urine biomarker panel test. 
 
Previous studies complementing our work have focused on identification of biomarker 
combinations reflective of LN histological subtypes in patients with biopsy proven LN. 
Brunner et al investigated 28 childhood onset and 48 adult-onset SLE patients, 
assessing biomarker combinations differentiating biopsy defined activity, chronicity or 
membranous LN in samples taken within 2 months of biopsy. The best predictive ability 
detected was for LN activity, when MCP-1, AGP, ceruloplasmin and urine protein to 
creatinine ratio were considered together (AUC 0.850) [29]. Within the UK JSLE 
Cohort and the ELC, we have demonstrated stronger AUC values (0.920 and 0.991) for 
identification of active LN with the combination of urinary AGP, ceruloplasmin, 
LPGDS and transferrin. This supports the importance of a combination-approach to 
urinary biomarkers in LN, in these JSLE cohorts. In our present study, when the results 
from both the UK and ELC are pooled, VCAM-1 adds to the diagnostic ability of the 
above biomarker panel. This indicates that further investigation of the role of VCAM-
1 in combination with other biomarkers for discriminating active LN in children is 
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required. The UK JSLE Cohort was predominately Caucasian and Indian, whereas the 
ELC cohort was mainly African American and Hispanic. Notably, African and African 
American patients often have more severe kidney involvement in SLE [4,34,42]. 
Interestingly within our study, the optimal biomarker panel performed even better in 
the validation ELC than the exploratory UK JSLE Cohort. 
 
More recently, Brunner et al have looked at additional biomarkers in samples taken at 
the time of biopsy from 47 children with with ISN/RPS class II-V LN. They 
demonstrated NGAL, MCP-1, ceruloplasmin, adiponectin, hematopexin and KIM-1 to 
be the best predictors of LN activity status as assessed by the National Institute for 
Health Activity Index (NIH-AI), proposing a biomarker based Renal Activity Index 
for Lupus (RAIL) algorithm [30]. Our current study looked at a sub-set of these 
markers looking at their ability to identify BILAG defined active LN rather than NIH-
AI status. These promising results of Brunner et al require further validation in larger 
prospective, multi-ethnic cohorts. In contrast to the markers validated in our current 
study, it remains unclear whether these biomarkers would be able to differentiate 
patients with active LN versus in-active LN, as all patients in the above study had 
definite biopsy-defined LN. 
 
Our data demonstrate the key utility of urinary biomarkers in monitoring of LN. We 
have demonstrated and validated an excellent panel of biomarkers which differentiate 
JSLE patients with active LN and no current LN. As discussed above, Brunner et al 
have also proposed  a distinct biomarker panel which accurately correlates with NIH-
AI status. A large international prospective study or clinical trial is therefore 
warranted. This would longitudinally assess the biomarkers validated in the current 
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study for initial indentification of active LN, followed by assement of LN severity 
using the additional markers included in the RAIL as a proxy for histological changes. 
An international collaborative study will most probably be needed to be sufficiently 
powered given the multiplicity of biomarkers studied, distinct kidney biopsy features 
seen and the ethnic differences seen in JSLE severity. 
 
In our current study we could not demonstrate a significant difference in urinary 
NGAL levels between those with active LN / non-LN patients in either the UK or 
ELC. This is in contrast with previous work which has shown NGAL to be highly 
sensitive / specific for identificantion of biopsy proven LN in children [26]. These 
results may be explained by differences in the timing of the sample and the outcome 
measures used. Urinary NGAL has previuosly been shown to be a useful predictor of 
impending flare in both the UK JSLE Cohort [26], and an adult SLE study of the ELC 
which included a University College London validation cohort [43]. Kiani et al were 
also unable to detect an association between urinary NGAL and LN in a prospective 
study including 107 adult SLE patients [44]. These observations may be due to 
urinary NGAL levels peaking before flares, and receeding before it becomes clinically 
detectable [45]. Urinary NGAL has also been demonstrated as a marker of renal 
damage in LN [46], which may also explain why patients with a history of biopsy 
proven LN have higher urinary NGAL levels. These observations suggest that NGAL 
requires further testing longitudinally as part of a urine biomarker panel despite the 
results seen in the current study, as it may able to predict active nephrits and in-active 
nephritis occurence. 
 
It is interesting to consider the origin and renal-specificity of the novel biomarkers. 
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AGP belongs to the immunocalin family, a group of immunomodulatory binding 
proteins. AGP is mainly produced by the liver, but has also been reported in other cell 
types (macrophages [47], endothelial cells [48], and monocytes [49]). In active LN, 
increased production as part of the acute phase response, coupled with production by 
cells infiltrating the kidney, may be responsible for the high urinary levels 
demonstrated. Transferrin and ceruloplasmin are plasma proteins, primarily 
responsible for carrying iron and copper respectively. Differing from albumin in terms 
of their molecular radii and isoelectric points, urinary ceruloplasmin and transferrin 
have been shown to predict the onset of microalbuminuria in diabetic nephropathy 
[50]. LPGDS, a member of the lipocalin superfamily responsible for prostaglandin D2 
production, is similar to albumin in chemical properties but it is also much smaller 
[51]. In type-2 diabetes, urinary LPGDS has been shown to increase in the early 
stages of kidney injury [52]. Urinary VCAM-1 levels have previously been shown to 
be higher than blood levels, suggesting that the inflamed kidney may represent an 
important source of urinary VCAM-1 [33]. 
 
Certain limitations of our study warrant recognition and should be addressed in future 
work. As our definition of active LN was based on the composite renal BILAG score, 
calculated from proteinuria, GFR, blood pressure, active urine sediment, plasma 
creatinine and recent biopsy findings, we could not directly compare such traditional 
markers with the novel urinary biomarkers studied. Due to the cross-sectional nature 
of this study we are unable to comment on the relationship of such biomarkers with 
other stages of the fluctuating LN disease course (e.g. prediction of flare / remission). 
Validation in a larger, longitudinal, prospectively collected study is therefore 
necessary, including children and young people with the full range of mild, severe and 
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in-active disease phenotypes from a range of patient cohorts (including Asian and 
African cohorts). With further prospective validation, it may become apparent that 
fewer biomarkers together can produce acceptable accuracy for active LN 
identification (e.g. AGP and CP) due to the level of correlation seen between 
biomarkers (especially for Cohort 2). This would potentially make it a simpler point 
of care testing device for biomarker quantification. Concurrent investigation of the 
role of such biomarkers in vitro or in LN mouse models, will also help to improve 
understand of LN pathophysiology. 
 
Conclusions 
JSLE patients have significant renal involvement and the potential to develop 
irreversible renal damage as the result of LN relapses that are either un-recognized, 
not identified early enough, or treated sufficiently [4,53]. This study has demonstrated 
and validated, a renal-specific excellent novel urine biomarker panel for recognition 
of active LN in two ethnically diverse JSLE populations, providing considerable 
strength to these findings. Further validation in larger, longitudinal, prospectively 
collected studies is required to define biomarker profiles that predict LN relapses and 
response to treatment. It is anticipated that a future urinary biomarker point of care 
testing device will help to improve the renal outcomes for JSLE patients through 
biomarker led renal monitoring in routine clinical practice. 
 
Figure Legends 
Fig 1 Distribution of biomarker concentrations in active / non-LN patients from 
Cohorts 1 & 2. Median value for each group shown by horizontal line. Mann 
Whitney-U tests used to compare distribution of biomarker concentrations between 
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patient groups within each cohort. A Bonferroni adjustment was applied to account 
for multiple testing, corrected p-values are reported (pc). VCAM-1 biomarker data not 
available from 1 active-LN patient from Cohort 1. NGAL data not available from 3 
active LN and 15 non-LN patients from Cohort 1 
 
Fig 2 Urine biomarker concentrations in patients with / without extra-renal 
JSLE activity. Biomarker concentrations standardised to urinary creatinine and 
expressed as median values. Mann Whitney U tests used to compare biomarker 
concentrations between patient groups. A Bonferroni adjustment was applied to 
account for multiple testing, corrected p-values are reported (pc). VCAM-1 
measurement missing from 1 patient. NGAL data not available from 3 active LN and 
15 non-LN patients 
 
Fig 3 ROC generated from the optimal binary logistic regression model when 
data from both cohorts combined. Optimal model includes AGP, Ceruloplasmin, 
LPGDS, TF and VCAM-1 (AUC = 0.952) 
 
Fig 4 Urine biomarker concentrations in cohort 2 patients with LN and no recent 
biopsy (BILAG defined active LN) versus biopsy defined active-LN. LN & biopsy 
patients, n=12. LN no biopsy, n=11 
 
On-line resource 1 Urine biomarker concentrations standardised to urinary 
creatinine in active and non-LN patients from both cohorts 
 
On-line resource 2 Correlation between urine biomarkers in cohorts 1 and 2 
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On-line resource 3 Urine biomarker concentrations (standardised to urinary 
creatinine) according to renal BILAG score in patients from the UK exploratory 
cohort. 
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